Komori
PRISM BioLab (206A) · InitiativeFirst stated

Drug Discovery Target Selection and Development Advice from the Scientific Advisory Board

First written in FY2025. . Latest entry: FY2025.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
R&D Guidance from the Scientific Advisory BoardA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2025First statedAnnual report

    「In selecting drug discovery targets, we seek to improve the probability of success by obtaining advice from the Scientific Advisory Board (an advisory committee providing scientific advice).」

    The company disclosed a framework for obtaining scientific advice to select drug discovery targets and improve the probability of success in research and development.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for PRISM BioLab yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Drug Discovery Target Selection and Development Advice from the Scientific Advisory Board | PRISM BioLab Co.,LTD (206A) | Komori